Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19

• Autores principales: Kei Irie (Autor), Atsushi Nakagawa (Autor), Hirotoshi Fujita (Autor), Ryo Tamura (Autor), Masaaki Eto (Autor), Hiroaki Ikesue (Autor), Nobuyuki Muroi (Autor), Keisuke Tomii (Autor), Tohru Hashida (Autor)
• Formato: Libro
• Publicado: Wiley, 2020-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Since December 2019, a novel coronavirus (severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID‐19). The antiretroviral drug favipiravir (FPV) has been experimentally used for...